Eligibility for anti‐fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing

Background and objective Publicly funded therapy for idiopathic pulmonary fibrosis (IPF) relies on percentage predicted values from pulmonary function testing, for example Australian patients must have a forced vital capacity ≥50% (%FVC), transfer factor of the lung for carbon monoxide ≥ 30% (%TLco) and forced expiratory volume in 1 s (FEV 1 )/FVC ratio > 0.7. Despite defined cut‐off values, no jurisdiction prescribes a reference equation for...